INOInovio Pharmaceuticals
About Inovio Pharmaceuticals
Inovio Pharmaceuticals (NASDAQ:INO) is a biotechnology firm focused on the discovery, development, and commercialization of DNA-based immunotherapies and vaccines for infectious diseases and cancer. The company leverages its proprietary plasmid DNA technology to stimulate robust and specific immune responses. Inovio's pipeline includes candidates for HPV-associated diseases, cancer, and infectious diseases such as COVID-19. With a commitment to global health, Inovio aims to innovate and make accessible new vaccines and therapies that can change the course of human diseases. Additionally, the company collaborates with industry leaders and organizations worldwide to advance and expand its reach in public health.
What is INO known for?
Snapshot
Public US
Ownership
1999
Year founded
262
Employees
Plymouth Meeting, United States
Head office
1 of 3
US Rank
Unknown
Sector
N/A
Sector rank
Loading Map...
Operations
All Locations
United States
Produtos e/ou serviços de Inovio Pharmaceuticals
- INO-4800, a DNA vaccine candidate for COVID-19, designed to precisely target the SARS-CoV-2 virus.
- VGX-3100, a DNA-based immunotherapy for the treatment of HPV-related precancers.
- Cellectra, a proprietary smart device for delivering DNA vaccines and therapeutics directly into the skin.
- INO-5401, a combination therapy targeting glioblastoma, a lethal brain cancer, using multiple immunotherapeutic agents.
- INO-5151, a DNA-based therapy aimed at treating prostate cancer by targeting specific cancer antigens.
- DNA medicines platform, providing rapid development of vaccines and therapies for infectious diseases and cancer.
equipe executiva do Inovio Pharmaceuticals
- Dr. Jacqueline E. Shea Ph.D.CEO, President & Director
- Mr. Peter D. KiesChief Financial Officer
- Dr. Michael Sumner B.S., M.B.A., M.D.Chief Medical Officer & Head of Development
- Dr. Laurent M. Humeau Ph.D.Chief Scientific Officer & Chairman of the Scientific Advisory Board
- Thomas HongManager of Investor Relations
- Mr. Robert L. Crotty J.D.General Counsel, Corporate Secretary & Chief Compliance Officer
- Mr. E. J. Brandreth MBASenior Vice President of Quality Assurance
- Dr. Jeffrey SkolnikSenior Vice President of Clinical Development
- Mr. Robert J. Juba Jr.Senior Vice President of Biological Manufacturing & Clinical Supply Management
- Mr. Shawn D. Bridy M.A., M.B.A.Senior Vice President of Business Development